Claims for Patent: 10,849,956

Summary for Patent: 10,849,956

Title:	Glycopeptide compositions
Abstract:	Solutions comprising a glycopeptide antibiotic, for example Vancomycin, and an amino acid or amino acid derivative such as N-acetyl-Glycine or N-acetyl-D-Alanine are provided. These solutions are stable or stabilized for long-term periods at conditions of normal use and storage, and can be formulated as pharmaceutical solutions for use in subjects. Methods of manufacturing and using these solutions are also provided, as are methods of stabilizing a glycopeptide antibiotic, for example Vancomycin, using amino acids or amino acid derivatives such as N-acetyl-Glycine or N-acetyl-D-Alanine.
Inventor(s):	Jasprica; Ivona (Zagreb, HR), Keser; Sabina (Zagreb, HR), Pindric; Katarina (Sesvete, HR)
Assignee:	Xellia Pharmaceuticals APS (N/A)
Application Number:	16/216,446
Patent Claims:	1. A stable aqueous pharmaceutical composition comprising about 0.5-5% w/V vancomycin, and N-acetyl-D-Alanine; wherein the pharmaceutical composition is stable for at least about 10 weeks at about 25 degrees Celsius, wherein the amount of vancomycin remaining in the pharmaceutical composition at about 10 weeks is at least 90% and further wherein (i) the composition has a pH of 4.5-5.5 and/or (ii) the composition comprises an amino acid. 2. The stable aqueous pharmaceutical composition of claim 1, wherein the composition has a pH of 4.5-5.5. 3. The stable aqueous pharmaceutical composition of claim 1, wherein the molar ratio of N-acetyl-D-Alanine to vancomycin is about 1:1-30:1. 4. The stable aqueous pharmaceutical composition of claim 3, wherein the amount of the vancomycin remaining is determined by liquid chromatography in accordance with USP 36-NF 31. 5. The stable aqueous pharmaceutical composition of claim 1, wherein the composition comprises an amino acid. 6. The stable aqueous pharmaceutical composition of claim 5, wherein the amino acid is chosen from the group consisting of D-Alanine, D-Serine, D-Leucine, D-Valine, L-Lysine, D-Lysine, L-Ornithine, D-Ornithine and L-Arginine. 7. The stable aqueous pharmaceutical composition of claim 5, wherein the amino acid is L-Lysine. 8. The stable aqueous pharmaceutical composition of claim 5, wherein the composition has a pH of 4.5-5.5. 9. The stable aqueous pharmaceutical composition of claim 5, wherein the molar ratio of N-acetyl-D-Alanine to vancomycin is about 1:1-30:1. 10. The stable aqueous pharmaceutical composition of claim 5, wherein the molar ratio of the amino acid to vancomycin is about 1:1-20:1. 11. The stable aqueous pharmaceutical composition of claim 9, wherein the amount of the vancomycin remaining is determined by liquid chromatography in accordance with USP 36-NF 31. 12. A stable aqueous pharmaceutical composition comprising about 0.5-5% w/V vancomycin; N-acetyl-D-Alanine; and L-lysine, wherein the pharmaceutical composition is stable for: (a) at least about 3 months at about 25 degrees Celsius, wherein the amount of vancomycin remaining in the pharmaceutical composition at 3 months is at least 85%; or (b) at least about 12 months at about 25 degrees Celsius, wherein the amount of vancomycin remaining in the pharmaceutical composition at about 12 months is at least 85%. 13. The stable aqueous pharmaceutical composition of claim 12, wherein the composition has a pH of about 4.5-5.5. 14. The stable aqueous pharmaceutical composition of claim 12, wherein the composition comprises about 0.5% w/V of vancomycin and a pharmaceutically acceptable organic solvent comprising about 1.8% V/V of polyethylene glycol. 15. The stable aqueous pharmaceutical composition of claim 12, wherein the molar ratio of N-acetyl-D-Alanine to vancomycin is about 1:1-30:1. 16. The stable aqueous pharmaceutical composition of claim 12, wherein the molar ratio of the L-Lysine to vancomycin is about 1:1-20:1. 17. The stable aqueous pharmaceutical composition of claim 12, wherein the amount of the vancomycin remaining is determined by liquid chromatography in accordance with USP 36-NF 31. 18. A stable aqueous pharmaceutical composition comprising about 0.5-5% w/V vancomycin; N-acetyl-D-Alanine; and L-lysine, wherein the pharmaceutical composition is stable: (a) at least about 3 months at about 25 degrees Celsius, wherein the amount of vancomycin remaining in the pharmaceutical composition at 3 months is at least 90%; or (b) at least about 12 months at about 25 degrees Celsius, wherein the amount of vancomycin remaining in the pharmaceutical composition at about 12 months is at least 85%. 19. The stable aqueous pharmaceutical composition of claim 18, wherein at about 12 months the amount of the vancomycin remaining is at least 90%. 20. The stable aqueous pharmaceutical composition of claim 18, wherein the composition has a pH of about 4.5-5.5. 21. The stable aqueous pharmaceutical composition of claim 18, wherein the composition comprises about 0.5% w/V of vancomycin and a pharmaceutically acceptable organic solvent comprising about 1.8% V/V of polyethylene glycol. 22. The stable aqueous pharmaceutical composition of claim 18, wherein the molar ratio of N-acetyl-D-Alanine to vancomycin is about 1:1-30:1. 23. The stable aqueous pharmaceutical composition of claim 18, wherein the molar ratio of the L-Lysine to vancomycin is about 1:1-20:1. 24. The stable aqueous pharmaceutical composition of claim 22, wherein the amount of the vancomycin remaining is determined by liquid chromatography in accordance with USP 36-NF 31.